Alnylam Presents Liver Cancer Drug Data at ASCO

Among the findings from the ongoing study was the suggestion of an anti-VEGF effect in the majority of treated patients.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.